Cancer Prevention and Screening Principles

Cancer prevention and screening principles describe how the burden of cancer is reduced before it becomes incurable — by removing causes (primary prevention) and by detecting cancer or its precursors early enough to change outcomes (secondary prevention through screening). A central part of the topic is the set of criteria, originating with Wilson and Jungner, that determine when screening an apparently healthy population is justified and when it may do more harm than good.

Definition

Cancer prevention comprises actions that reduce the incidence (primary), detect and treat early disease (secondary), or limit complications of established disease (tertiary); cancer screening is the systematic application of a test to an asymptomatic population to identify individuals likely to have a cancer or precursor lesion who then undergo further evaluation.

Scope

The topic covers the levels of prevention, the rationale and prerequisites for population screening, the performance measures used to evaluate screening tests and programmes, and the characteristic biases and harms — lead-time bias, length bias, and overdiagnosis — that complicate the evaluation of early detection. It is reference material on principles and is not a schedule of who should be screened or how.

Core questions

• What distinguishes primary, secondary, and tertiary prevention of cancer?
• What conditions must a cancer and a test meet before population screening is justified?
• How are screening tests and programmes evaluated, and which biases distort naive comparisons of survival?
• What are the harms of screening, including false positives and overdiagnosis, and how are benefits and harms balanced?

Key concepts

• Primary, secondary, and tertiary prevention
• Wilson-Jungner criteria
• Sensitivity and specificity
• Positive and negative predictive value
• Lead-time bias
• Length-time bias
• Overdiagnosis and overtreatment
• Mortality reduction as the key endpoint

Key theories

Wilson-Jungner screening criteria

Screening is justified only when the condition is an important health problem with a recognisable early stage, a suitable and acceptable test exists, an accepted treatment improves outcomes when applied early, and the programme's benefits outweigh its costs and harms.

Overdiagnosis in early detection

Screening can detect indolent cancers that would never have caused symptoms or death, leading to overdiagnosis and overtreatment, so apparent survival gains must be interpreted against this and against lead-time and length biases.

Mechanisms

Primary prevention lowers incidence by removing causes (for example, reducing tobacco use or vaccinating against oncogenic infection); secondary prevention reduces mortality by detecting cancer or precursor lesions early, when treatment is more effective. Whether screening helps depends on disease and test characteristics codified by Wilson and Jungner, and on demonstrating a genuine reduction in disease-specific mortality rather than merely longer survival from diagnosis. Three biases threaten the latter judgement: lead-time bias (earlier diagnosis lengthens measured survival without postponing death), length bias (screening preferentially detects slower-growing, better-prognosis tumours), and overdiagnosis (detection of cancers that would never have become clinically significant). Programmes are therefore evaluated by their effect on mortality and net benefit, balancing detection against false positives, harms of workup, and overtreatment.

Clinical relevance

These principles explain why some cancers are screened for at the population level and others are not, and why screening recommendations weigh benefits against harms rather than assuming earlier is always better. The entry presents the reasoning behind prevention and screening as reference knowledge; it does not state which individuals should be screened, at what age, or how often, which are matters for current guidelines and clinical judgement.

Epidemiology

Screening programmes for cervical and colorectal cancer, among others, have been associated with reductions in incidence or mortality at the population level, while debates over breast and prostate screening illustrate the difficulty of separating true mortality benefit from overdiagnosis. In parallel, primary prevention targeting modifiable causes addresses a large, potentially avoidable share of the overall cancer burden.

History

The modern logic of screening was set out in Wilson and Jungner's 1968 World Health Organization monograph, whose criteria still anchor screening policy. As organised cancer-screening programmes expanded, methodologists clarified how lead-time and length biases inflate survival comparisons and, from the late twentieth century onward, brought the problem of overdiagnosis to the centre of debate, reframing screening evaluation around mortality reduction and net benefit rather than detection alone.

Debates

How should overdiagnosis change cancer-screening policy?

Because some screen-detected cancers would never have caused harm, programmes can generate overdiagnosis and overtreatment; how large this effect is, and how to weigh it against mortality benefit, remains contested for several common cancers.

Key figures

• James Maxwell Glover Wilson
• Gunner Jungner
• H. Gilbert Welch
• William Black

Seminal works

• wilson-jungner-1968
• welch-2010

Frequently asked questions

Why is mortality reduction, not survival, the key measure of a screening test?

Because earlier diagnosis automatically lengthens measured survival (lead-time bias) and screening preferentially catches slower-growing cancers (length bias), survival can improve even when screening saves no lives; a genuine fall in disease-specific mortality is the more reliable evidence of benefit.

What is overdiagnosis in cancer screening?

It is the detection of a cancer that would never have caused symptoms or death in the person's lifetime; such cases inflate apparent screening success while exposing people to the harms of unnecessary diagnosis and treatment.